SCHEMBL20068775

SCHEMBL20068775

Clc1ccccc1-c1ccc(-c2ncc(-c3ccccc3Cl)cn2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 1/20 0.56
▸ USP7 Q93009 1/20 0.51
▸ NPC1 O15118 6/20 0.48
▸ RAB9A P51151 6/20 0.48
▸ SMN1; SMN2 Q16637 4/20 0.48
▸ NFKB1 P19838 2/20 0.48
▸ NFKB2 Q00653 2/20 0.48
▸ RELA Q04206 2/20 0.48
▸ EGLN1 Q9GZT9 1/20 0.47
▸ CNR2 P34972 1/20 0.46
▸ MAOB P27338 2/20 0.46
▸ DEGS1 O15121 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ TRPA1 O75762 1/20 0.44
▸ MAP4K4 O95819 1/20 0.43
▸ TP53 P04637 2/20 0.42
▸ HPGD P15428 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ ALPL P05186 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10939627 0.88 CYP2A6 (0.54) CYP2A6USP7NPC1RAB9ASMN1; SMN2
SCHEMBL10899864 0.81 CYP2A6 (0.56) CYP2A6USP7NPC1RAB9ASMN1; SMN2
SCHEMBL31373340 0.78 CYP2A6 (0.71) CYP2A6NPC1RAB9ASMN1; SMN2MAOB
SCHEMBL11477196 0.78 USP7 (0.53) CYP2A6USP7NPC1RAB9ASMN1; SMN2
SCHEMBL20068878 0.78 USP7 (0.53) CYP2A6USP7NPC1RAB9ASMN1; SMN2
SCHEMBL21742616 0.78 CYP2A6 (0.71) CYP2A6NPC1RAB9ASMN1; SMN2MAOB
SCHEMBL5318630 0.78 USP7 (0.53) CYP2A6USP7NPC1RAB9ASMN1; SMN2
SCHEMBL10896655 0.78 USP7 (0.53) CYP2A6USP7NPC1RAB9AEGLN1
SCHEMBL9942331 0.76 NPC1 (0.73) NPC1RAB9ASMN1; SMN2NFKB1NFKB2
SCHEMBL20068644 0.76 MAPK1 (0.56) NPC1RAB9ASMN1; SMN2NFKB1NFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526227-B1 BINUCLEAR METAL COMPLEXES AND ELECTRONIC DEVICES, IN PARTICULAR ORGANIC ELECTROLUMINESCENT DEVICES CONTAINING SAID METAL COMPLEXES MERCK PATENT GMBH (DE) 2020-06-03 — — EP disclosed
US-20200052213-A1 BINUCLEAR METAL COMPLEXES AND ELECTRONIC DEVICES, IN PARTICULAR ORGANIC ELECTROLUMINESCENT DEVICES CONTAINING SAID METAL COMPLEXES MERCK PATENT GMBH (DE) 2020-02-13 — — US disclosed
WO-2018069196-A1 BINUCLEAR METAL COMPLEXES AND ELECTRONIC DEVICES, IN PARTICULAR ORGANIC ELECTROLUMINESCENT DEVICES CONTAINING SAID METAL COMPLEXES MERCK PATENT GMBH (DE) 2018-04-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200052213-A1 BINUCLEAR METAL COMPLEXES AND ELECTRONIC DEVICES, IN PARTICULAR ORGANIC ELECTROLUMINESCENT DEVICES CONTAINING SAID METAL COMPLEXES BICRA, NCLN, IMMT CYP2A6 4527/4885USP7 4590/4885NPC1 3686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback